G
Giovanni Barosi
Researcher at University of Pavia
Publications - 352
Citations - 21433
Giovanni Barosi is an academic researcher from University of Pavia. The author has contributed to research in topics: Myelofibrosis & Essential thrombocythemia. The author has an hindex of 69, co-authored 334 publications receiving 19225 citations.
Papers
More filters
Journal ArticleDOI
Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors
Stefania Bregante,Alida Dominietto,Anna Ghiso,Anna Maria Raiola,Francesca Gualandi,Riccardo Varaldo,Carmen Di Grazia,Teresa Lamparelli,Silvia Luchetti,Simona Geroldi,L. Casarino,Sarah Pozzi,Elisabetta Tedone,Maria Teresa Van Lint,Federica Galaverna,Giovanni Barosi,Andrea Bacigalupo +16 more
TL;DR: The outcome of allografts in patients with myelofibrosis has improved in recent years because of a reduction of both TRM and relapse, with modifications in donor type and conditioning regimen.
Journal ArticleDOI
In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes
Alessandra Balduini,Alessandra Balduini,Stefania Badalucco,Maria Teresa Pugliano,Denis V. Baev,Annalisa De Silvestri,Marco Cattaneo,Vittorio Rosti,Giovanni Barosi +8 more
TL;DR: Profound differences in megakaryocyte morphology and proplatelet formation distinguish PMF, both fibrotic and prefibrotic, from ET and PV, and MPNs are associated with high megakARYocyte proliferative potential.
Journal ArticleDOI
A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.
Srdan Verstovsek,Francesco Passamonti,Alessandro Rambaldi,Giovanni Barosi,Peter Rosen,Richard Levy,Edward C Bradley,Lee Schacter,William M. Garrett,Kris Vaddi,Nancy Contel,Elisa Rumi,Elisabetta Gattoni,Mario Cazzola,Hagop M. Kantarjian,Tiziano Barbui,Alessandro M. Vannucchi +16 more
TL;DR: INCB018424, a potent, selective inhibitor of JAK1 and JAK2, with demonstrated efficacy in MF (PMF, post-PV & post-ET MF), was evaluated for clinical activity in patients refractory to or intolerant of treatment with hydroxyurea.
Journal ArticleDOI
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results
Srdan Verstovsek,Francesco Passamonti,Alessandro Rambaldi,Giovanni Barosi,Elisa Rumi,Elisabetta Gattoni,Lisa Pieri,Hui-Ling Zhen,Muriel Granier,Albert Assad,Mario Cazzola,Hagop M. Kantarjian,Tiziano Barbui,Alessandro M. Vannucchi +13 more
TL;DR: Essential thrombocythemia (ET) is a Philadelphia chromosome–negative myeloproliferative neoplasm (MPN) characterized by persistent thromBocytosis, excessive bone marrow megakaryocyte proliferation, and normal erythrocyte mass.
Journal ArticleDOI
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Giovanni Barosi,Angelo Michele Carella,Mario Lazzarino,Monia Marchetti,Maurizio Martelli,Alessandro Rambaldi,Corrado Tarella,Umberto Vitolo,Pier Luigi Zinzani,Sante Tura +9 more
TL;DR: The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of nodal diffuse large B-cell non Hodgkin lymphomas (DLBCL) were formulated by an Advisory Committee (AC) and approved by an Expert Panel (EP) composed of eight senior hematologists as mentioned in this paper.